T

Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867

Watchlist Manager
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
Watchlist
Price: 8.15 CNY -0.49%
Market Cap: 15.9B CNY
Have any thoughts about
Tonghua Dongbao Pharmaceutical Co Ltd?
Write Note

Tonghua Dongbao Pharmaceutical Co Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tonghua Dongbao Pharmaceutical Co Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
T
Tonghua Dongbao Pharmaceutical Co Ltd
SSE:600867
Short-Term Investments
ÂĄ35m
CAGR 3-Years
-53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Short-Term Investments
ÂĄ2.4B
CAGR 3-Years
-36%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Short-Term Investments
ÂĄ279.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Short-Term Investments
ÂĄ973.2m
CAGR 3-Years
-34%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Short-Term Investments
ÂĄ2.2B
CAGR 3-Years
-37%
CAGR 5-Years
-24%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tonghua Dongbao Pharmaceutical Co Ltd
Glance View

Market Cap
16.2B CNY
Industry
Pharmaceuticals

Nestled in the bustling heart of China's pharmaceutical industry, Tonghua Dongbao Pharmaceutical Co., Ltd. has carved out a distinctive niche in the world of diabetes care. Since its inception, the company has been focused on developing, manufacturing, and distributing a range of innovative pharmaceutical products, primarily concentrating on insulin products. With its headquarters strategically located in Tonghua City—a region known for its rich medicinal resources—the company integrates advanced biotechnological processes with traditional pharmaceutical practices. Tonghua Dongbao’s competitive edge lies in its ability to harness cutting-edge technology to produce high-quality insulin products efficiently, allowing it to tap into the rapidly growing domestic and international markets. As diabetes continues to be a major global health challenge, this focus on insulin has positioned the company as a critical player in the fight to manage and treat this chronic disease. Their revenue model is underscored by a keen focus on the production of insulin and its analogs, which represent a significant portion of its sales. Beyond insulin, Tonghua Dongbao also produces a range of other pharmaceuticals, contributing to a diversified product portfolio that supports steady revenue streams. Importantly, the company’s investment in R&D has led to a robust pipeline of new and improved therapeutics aimed at expanding their reach and maintaining competitive advantage. Through strategic partnerships and collaborations, both within China and internationally, Tonghua Dongbao continues to amplify its market presence. In doing so, it exemplifies a commitment not only to financial growth but also to advancing healthcare outcomes for millions of diabetes patients around the globe.

Intrinsic Value
10.09 CNY
Undervaluation 19%
Intrinsic Value
Price
T

See Also

What is Tonghua Dongbao Pharmaceutical Co Ltd's Short-Term Investments?
Short-Term Investments
35m CNY

Based on the financial report for Sep 30, 2024, Tonghua Dongbao Pharmaceutical Co Ltd's Short-Term Investments amounts to 35m CNY.

What is Tonghua Dongbao Pharmaceutical Co Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 3Y
-53%

Over the last year, the Short-Term Investments growth was -36%. The average annual Short-Term Investments growth rates for Tonghua Dongbao Pharmaceutical Co Ltd have been -53% over the past three years .

Back to Top